MicroPort® EP Products Debut in First Procedure in Kazakhstan

Taraz, Kazakhstan, 7 September 2021 — Shanghai MicroPort® EP MedTech Co., Ltd. (MicroPort EP) recently announced its debut in Kazakhstan, following the completion of the first procedure using MicroPort EP products since its entry into the country. The FireMagic™ Cardiac RF Ablation Catheter, the EasyFinder™ Steerable Curve Diagnostic Catheter, the PathBuilder™ Steerable Introducer, the PathBuilder™ Transseptal Guiding Introducer and PathBuilder™ Transseptal Needle were successfully used in an atrioventricular nodal reentrant tachycardia (AVNRT) procedure by a team of electrophysiologists from Zhurek Hospital in Kazakhstan.

The FireMagic™ Cardiac RF Ablation Catheter and other products were subsequently used in four other procedures, including for premature ventricular contractions, performed by the team at Zhurek Hospital. These products received favorable feedback from the team, who acknowledged their robust performance and ease of use during the procedures.

Kazakhstan is a major hub along the “Belt and Road” with a population of nearly 20 million. A number of products independently developed by MicroPort EP were approved for marketing by the Ministry of Health of Kazakhstan in May 2021. The completion of the first implantation marks the recognition of MicroPort EP products in the Kazakhstan market, and lays a solid foundation for its expansion into Central Asia.

About Shanghai MicroPort® EP MedTech Co., Ltd

Shanghai MicroPort® EP MedTech Co., Ltd (MicroPort EP) is a subsidiary of MicroPort Scientific Corporation (00853.HK). As the leading electrophysiological medical device company in China, MicroPort EP is committed to providing quality and affordable products and services. To date, MicroPort EP products have reached more than 20 countries and regions including Europe, Oceania, Africa, South America and Asia. In the future, MicroPort EP will continue to build a differentiated product portfolio and expand its global reach, offering integrated solutions for diagnosis and therapy of EP interventions to more patients and doctors worldwide.